ImetelChat

Thanks for the thoughtful summary. We will learn more about efficacy as the results of IMbark and IMerge become better known beginning with the release of abstracts tomorrow and through ASH, and the efficacy we already know of from the earlier trials, especially the Mayo Pilot, still speaks loudly t...

biopearl, I share your astonishment. It is beyond my comprehension that the number of patients benefitting in the MDS trial isn't the real headline from the standpoint of a potential treatment. It's a fact that high transfusion burdens lead to poor outcomes. All the evidence so far is that Imetelsta...

Hi biopearl, I'm traveling and only have a second to post, but my thoughts run parallel to yours. I'm not looking at the data now, but when I did my conclusion was that it could be deduced from the data that was released that the transfusion burden was substantially reduced even among those patients...

Hi irish,- here's to excellent quality of life! And Fish, here's to you for excellent quality of site!

irish- very glad to have you on here, and to hear that John is doing well. I always wondered how you could put up with the hurtful posts at Yahoo!, but like many people who didn't post, I was always grateful that you did. Rooting for you and John and for happiness for your family became second natur...

Thanks for the nice comments- and for bringing my Annual Report post over here. In thinking the experience over the last few days, I really think Dr. Scarlett's answer to a question in the taped Q&A answer session that they need to get to "2nd Base" first was purposeful. He clarified that right away...

The table is set. It's kind of amazing that everything is coming together at a moment when the market is selling off. I've been in Geron for years, and it's taken amazing patience to wait for the opportunity the company now has. Some investors are just coming to Geron now, and they have no idea how ...